Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mongersen Mechanism of Action in Crohn's Disease
NCT02685683Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Apr 2016
- Primary completion
- Sep 2017
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of mongersen in Crohn's disease, sponsored by Celgene Corporation. Started Apr 2016; status: terminated.
02
Drugs
mongersen
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02685683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685683.